Your Antidepressant Isn't Working. Your Genes May Be Why.

CYP2D6 is one of your liver’s most important drug-processing enzymes. Its job is to break down a vast array of psychiatric medications: SSRIs like fluoxetine and paroxetine, tricyclic antidepressants, some SNRIs, antipsychotics, and opioids used for pain. Without it working efficiently, none of these drugs can be safely eliminated from your body.

Here’s the problem: CYP2D6 comes in many variants, including complete deletions, duplications, and partial-function versions. Poor metabolizers, roughly 7-10% of people of European ancestry, either lack the enzyme or have severely reduced versions. Poor metabolizers accumulate psychiatric medications to toxic levels even at standard doses. Ultra-rapid metabolizers have extra gene copies and burn through drugs so fast that standard doses never reach the brain.

What does this feel like? If you’re a poor metabolizer on a standard SSRI dose, you might experience tremors, severe sexual dysfunction, emotional numbness, or cognitive fog. If you’re ultra-rapid, you take your antidepressant and feel nothing within days or weeks, despite being told ‘these take 4-6 weeks to work.’

CYP2C19 metabolizes some of the most commonly prescribed antidepressants: citalopram, escitalopram, sertraline, paroxetine, and tricyclics like amitriptyline. It also metabolizes antipsychotics, anti-anxiety medications, and proton pump inhibitors. This enzyme is your body’s workhorse for psychiatric drugs.

The *2 and *3 variants produce little to no functional enzyme, making you a poor metabolizer. Roughly 2-15% of people carry poor-metabolizer variants, with rates highest in East Asian and Middle Eastern ancestry. Poor metabolizers accumulate CYP2C19-metabolized drugs in the blood at concentrations 3-4 times higher than fast metabolizers taking the same dose. The *17 variant creates ultra-rapid metabolizers who burn through these drugs too quickly.

You might not realize you’re a poor metabolizer because symptoms build gradually. You start citalopram at 20 mg, feel okay for a week, then begin experiencing emotional blunting, sexual side effects, or strange dream patterns. Your doctor increases the dose because ‘you need more time,’ and now you’re in a toxic range without realizing it.

CYP2C9 isn’t exclusively a psychiatric enzyme, but it metabolizes NSAIDs that psychiatrically ill patients often take for pain or inflammation, and it controls the breakdown of some antidepressants and anti-anxiety medications. More importantly, if you ever need warfarin (a blood thinner), this gene becomes critical for avoiding hemorrhage.

The *2 and *3 variants reduce enzyme function. Roughly 5-10% of people of European ancestry carry poor-metabolizer variants. Poor metabolizers need significantly lower doses of NSAIDs and warfarin to avoid accumulation and toxicity. If you’re a poor metabolizer and your psychiatrist prescribes a standard-dose antidepressant while you’re also taking an NSAID, the NSAID might inhibit CYP2C9 further, causing the psychiatric drug to accumulate unexpectedly.

You might experience unusual bleeding (if on warfarin), or stomach ulcers and GI bleeding from NSAID accumulation. If you’re taking both a CYP2C9-metabolized psychiatric drug and NSAIDs, you could see unexpected side effects from the psychiatric drug building up.

SLCO1B1 encodes a transporter protein on the surface of liver cells. Its job is to ferry drugs from the bloodstream into the liver where they can be metabolized and eliminated. Without efficient SLCO1B1 function, drugs stay in the bloodstream longer and reach higher concentrations than expected.

The *5 variant, particularly the rs4149056 C allele, reduces transporter function. Roughly 15% of the European population carries this variant. Carriers of the C allele have reduced hepatic drug uptake, causing psychiatric medications and statins to linger in the bloodstream at higher-than-expected concentrations. This increases the risk of side effects even at standard doses because the drug isn’t being cleared efficiently.

You might take a standard dose of an antidepressant and experience side effects that shouldn’t occur at that dose level. Or you might do well initially, but as the drug accumulates over weeks, side effects emerge. Your doctor might think you need a lower dose, but the real problem is your liver isn’t pulling the drug in efficiently.

VKORC1 encodes vitamin K epoxide reductase, the enzyme that recycles vitamin K and the direct target of warfarin (a blood thinner). Most psychiatric patients don’t take warfarin, but if you have atrial fibrillation, clotting disorders, or other conditions requiring anticoagulation, VKORC1 variants become critical.

The -1639G>A variant affects how sensitive your vitamin K recycling is to warfarin inhibition. The A allele, present in roughly 40% of the European population, reduces VKORC1 activity. A-allele carriers are highly warfarin-sensitive and require substantially lower doses to achieve the same anticoagulation as G-allele homozygotes. Standard warfarin dosing can cause dangerous bleeding in A-allele carriers.

If you carry the A allele and are prescribed warfarin while also taking psychiatric medications that interact with warfarin (like some SSRIs, which increase bleeding risk), you face compounded risk of hemorrhage at standard doses. You might bleed easily, develop bruises from minor trauma, or experience gastrointestinal bleeding.

MTHFR catalyzes a critical step in the methylation cycle, converting folate into a form your cells can use for DNA synthesis, methylation reactions, and neurotransmitter production. This gene is involved in cellular energy, mood regulation, and the breakdown of homocysteine, an inflammatory marker linked to depression and anxiety.

The C677T variant, present in roughly 40% of the European population, reduces MTHFR enzyme activity by 35-40%. C677T carriers have impaired folate-dependent metabolic pathways, reducing the efficiency of methylation reactions needed for optimal neurotransmitter balance and cellular energy production. This doesn’t directly slow drug metabolism, but it impairs the cellular machinery that supports mood regulation and medication response.

You might experience reduced antidepressant efficacy, persistent brain fog despite being on medication, emotional blunting, or treatment-resistant symptoms even when your psychiatrist adjusts doses correctly. Your depression or anxiety improves partially but plateaus. Standard medication helps, but you feel like something is still missing.